₹1,028.25
−1.36%NSE close, 16 Nov 2026
+173.98%
Sakar Healthcare is a small cap company, listed on NSE under the symbol SAKAR. At ₹1,028.25 a share, the market values the whole company at ₹2,288 crore.
In FY26, it reported sales of ₹252 crore and a net profit of ₹30 crore, an operating margin of 27.4%. Over the last three years, sales grew 23.6% a year and net profit grew 33.7% a year.
The market values the company at 53.4 times its profit over the last twelve months and 6.61 times its book value; its return on equity is 12.4% and its borrowings are 0.13 times its equity.
Promoters hold 51.70% of the shares. Foreign institutions hold 12.34%, and domestic institutions, mutual funds among them, 11.92%.
Over the past year the share price has risen 163.6%, and it is 16.4% below its 52-week high.
₹ crore. Consolidated figures.
Transcript
Link of Recording
Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 37.2 | 43.1 | 41.2 | 42.8 | 43.4 | 50.2 | 52.7 | 57.6 | 70.3 | 71.1 | 73.0 | 87.4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 28.2 | 32.1 | 30.5 | 31.3 | 31.7 | 34.5 | 40.0 | 46.2 | 51.8 | 44.9 | 51.7 | 63.1 |
| Operating profit | 9.0 | 11.0 | 10.7 | 11.5 | 11.8 | 15.7 | 12.7 | 11.4 | 18.6 | 26.2 | 21.3 | 24.4 |
| Operating margin | 24.2% | 25.5% | 26.0% | 26.9% | 27.1% | 31.3% | 24.1% | 19.7% | 26.4% | 36.9% | 29.1% | 27.9% |
| Other income | 0.2 | 0.8 | 0.5 | 0.4 | 0.3 | 0.2 | 0.4 | 1.2 | 0.5 | 0.2 | 1.5 | 0.3 |
| Interest | 1.8 | 2.1 | 1.4 | 1.6 | 1.3 | 4.2 | 2.1 | 1.5 | 1.8 | 2.4 | 1.7 | 2.0 |
| Depreciation | 4.4 | 4.9 | 5.1 | 5.1 | 5.2 | 5.5 | 5.6 | 5.7 | 6.4 | 5.9 | 6.5 | 6.6 |
| Profit before tax | 3.0 | 4.8 | 4.7 | 5.1 | 5.5 | 6.2 | 5.4 | 5.4 | 11.0 | 18.1 | 14.6 | 16.0 |
| Tax | 0.9 | 1.7 | 2.3 | 0.3 | 0.9 | 0.5 | 0.7 | 0.8 | 0.7 | 7.0 | 4.3 | 4.7 |
| Net profit | 2.1 | 3.1 | 2.4 | 4.8 | 4.5 | 5.8 | 4.7 | 4.5 | 10.3 | 11.0 | 10.3 | 11.3 |
| EPS (₹) | 0.98 | 1.46 | 1.10 | 2.17 | 2.08 | 2.66 | 2.11 | 2.03 | 4.59 | 4.96 | 4.62 | 5.08 |
₹ crore, financial years to March.
| Line | FY20 S | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 83.0 | 94.7 | 128 | 133 | 153 | 178 | 252 |
| Expenses | 63.4 | 72.1 | 98.9 | 100 | 115 | 128 | 183 |
| Operating profit | 19.5 | 22.6 | 29.3 | 33.1 | 38.4 | 49.7 | 68.9 |
| Operating margin | 23.5% | 23.9% | 22.9% | 24.9% | 25.0% | 28.0% | 27.4% |
| Other income | 2.0 | 1.2 | 2.2 | 4.7 | 3.2 | 1.3 | 2.3 |
| Interest | 2.3 | 2.5 | 2.9 | 5.9 | 7.6 | 8.5 | 7.9 |
| Depreciation | 7.1 | 8.1 | 9.7 | 15.0 | 18.1 | 20.9 | 23.6 |
| Profit before tax | 12.2 | 13.2 | 18.9 | 16.9 | 15.9 | 21.5 | 39.8 |
| Tax | 2.6 | 2.6 | 3.8 | 4.9 | 4.2 | 4.0 | 9.3 |
| Net profit | 9.6 | 10.7 | 15.0 | 12.8 | 11.7 | 17.5 | 30.5 |
| EPS (₹) | 6.40 | 6.87 | 8.73 | 6.86 | 5.58 | 7.97 | 13.70 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 35.7 | 35.6 | 49.3 | 23.5 |
| From investing | −90.4 | −32.3 | −28.4 | −22.0 |
| From financing | 54.6 | −3.5 | −21.0 | −1.4 |
| Spent on fixed assets | −97.5 | −32.3 | 0 | −22.0 |
| Free cash flow | −61.8 | 3.3 | 49.3 | 1.4 |
Margins, returns, debt, tax and cash.
| Line | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 11.6% | 11.3% | 11.7% | 9.6% | 7.6% | 9.9% | 12.1% |
| Operating margin | 23.5% | 23.9% | 22.9% | 24.9% | 25.0% | 28.0% | 27.4% |
| Return on equity | – | – | – | 7.4% | 4.4% | 6.1% | 9.4% |
| Return on capital employed | – | – | – | 8.0% | 7.1% | 8.3% | 12.5% |
| Return on assets | – | – | – | 3.8% | 3.0% | 4.2% | 6.3% |
| Debt to equity | – | – | – | 0.64 | 0.26 | 0.26 | 0.17 |
| Interest coverage | 6.40 | 6.30 | 7.50 | 3.80 | 3.10 | 3.50 | 6.10 |
| Debt to assets | – | – | – | 0.33 | 0.18 | 0.18 | 0.11 |
| Current ratio | – | – | – | 1.03 | 1.21 | 1.40 | 1.28 |
| Quick ratio | – | – | – | 0.74 | 0.74 | 0.71 | 0.64 |
| Cash ratio | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset turnover | – | – | – | 0.40 | 0.39 | 0.43 | 0.52 |
| Fixed asset turnover | – | – | – | 0.50 | 0.49 | 0.58 | 0.79 |
| Inventory turnover | – | – | – | – | 3.00 | 1.90 | 1.80 |
| Receivables turnover | – | – | – | 6.00 | 7.30 | 5.80 | – |
| Gross margin | – | – | – | – | 45.4% | 53.7% | 51.0% |
| Cash from operations to profit | – | – | 239.0% | – | – | 203.0% | 162.0% |
| Effective tax rate | 21.3% | 19.3% | 19.8% | 29.0% | 26.6% | 18.7% | 23.3% |
The financial results for the period ended September 30, 2026.
Schedule of meet
Sakar s global export model expands with oncology products
Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th Sept 2026
Appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors of the Company for the term of 5 years w.e.f. September 22, 2026.
A copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 22, 2026
Schedule of meet on 18th Sept., 2026
Sakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 business partners
Notice of Annual General Meeting to be held on September 22, 2026